Evidence map›Paper›PMID 19479048›Full record

ArticlePloS one2009

Systemic inhibition of NF-kappaB activation protects from silicosis.

Michelangelo Di Giuseppe, Federica Gambelli, Gary W Hoyle, Giuseppe Lungarella, Sean M Studer, Thomas Richards, Sam Yousem, Ken McCurry, James Dauber, Naftali Kaminski and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Artificial Stone Associated Silicosis: A Systematic Review.International journal of environmental research and public health · 2019
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. The role of inflammation in silicosis.Frontiers in pharmacology · 2024
    Review
  11. Article
  12. Preclinical Mouse Model of Silicosis.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  13. Article
  14. Long-term survival following unilateral lung transplantation for end-stage silicosis relative to idiopathic pulmonary fibrosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022
    Article
  15. Caveolin-1 negatively regulates inflammation and fibrosis in silicosis.Journal of cellular and molecular medicine · 2022
    Article
  16. Review
  17. Article
  18. The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.Journal of molecular medicine (Berlin, Germany) · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Michelangelo Di GiuseppeDivision of Occupational and Environmental Medicine, Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Federica Gambelli
Gary W Hoyle
Giuseppe Lungarella
Sean M Studer
Thomas Richards
Sam Yousem
Ken McCurry
James Dauber
Naftali Kaminski
George Leikauf
Luis A Ortiz
University of Pittsburgh Medical Center · USUniversity of Pittsburgh · USUniversity of Louisville · USUniversity of Siena · IT

Funding

Improving our mechanistic understanding of Electronic-cigarette, or vaping, product use-associated lung injuryU01ES015675 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEIKAUF, GEORGE DOUGLAS · 2006 to 2020
$8.9M
TNF-alpha Signaling in Silica-Induced Lung FibrosisR01ES010859 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ORTIZ, LUIS ALBERTO · 2002 to 2012
$3.3M
New Molecular Targets in Pulmonary FibrosisR01HL073745 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAMINSKI, NAFTALI · 2003 to 2006
$2.8M
Genetic Determinants of Nickel-induced Lung InjuryR01ES010562 · NIEHS · UNIVERSITY OF CINCINNATI · PI LEIKAUF, GEORGE DOUGLAS · 2001 to 2005
$1.5M
GENETIC DETERMINATION OF ACUTE LUNG INJURYR01HL065612 · NHLBI · UNIVERSITY OF CINCINNATI · PI LEIKAUF, GEORGE DOUGLAS · 2000 to 2004
$1.5M
Growth Factor Protection in Acute Lung InjuryR01HL077763 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEIKAUF, GEORGE DOUGLAS · 2006 to 2009
$1.4M
Role of Metalloproteinases in Mucin Overproduction in COPDR01HL085655 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEIKAUF, GEORGE DOUGLAS · 2008 to 2011
$1.4M
Mesenchymal Stem Cells In The Treatment of Lung FibrosisR01HL071953 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ORTIZ, LUIS ALBERTO · 2005 to 2008
$1.3M
NHLBI NIH HHS HL071953NHLBI NIH HHS HL073745NHLBI NIH HHS R01 HL065612NHLBI NIH HHS R01 HL071953NHLBI NIH HHS R01 HL073745NHLBI NIH HHS R01 HL077763NHLBI NIH HHS R01 HL085655NIEHS NIH HHS ES10859NIEHS NIH HHS R01 ES010562NIEHS NIH HHS R01 ES010859NIEHS NIH HHS U01 ES015675
6 · The paper itself

Abstract

backgroundSilicosis is a complex lung disease for which no successful treatment is available and therefore lung transplantation is a potential alternative. Tumor necrosis factor alpha (TNFalpha) plays a central role in the pathogenesis of silicosis. TNFalpha signaling is mediated by the transcription factor, Nuclear Factor (NF)-kappaB, which regulates genes controlling several physiological processes including the innate immune responses, cell death, and inflammation. Therefore, inhibition of NF-kappaB activation represents a potential therapeutic strategy for silicosis. METHODS/

findingsIn the present work we evaluated the lung transplant database (May 1986-July 2007) at the University of Pittsburgh to study the efficacy of lung transplantation in patients with silicosis (n = 11). We contrasted the overall survival and rate of graft rejection in these patients to that of patients with idiopathic pulmonary fibrosis (IPF, n = 79) that was selected as a control group because survival benefit of lung transplantation has been identified for these patients. At the time of lung transplantation, we found the lungs of silica-exposed subjects to contain multiple foci of inflammatory cells and silicotic nodules with proximal TNFalpha expressing macrophage and NF-kappaB activation in epithelial cells. Patients with silicosis had poor survival (median survival 2.4 yr; confidence interval (CI): 0.16-7.88 yr) compared to IPF patients (5.3 yr; CI: 2.8-15 yr; p = 0.07), and experienced early rejection of their lung grafts (0.9 yr; CI: 0.22-0.9 yr) following lung transplantation (2.4 yr; CI:1.5-3.6 yr; p<0.05). Using a mouse experimental model in which the endotracheal instillation of silica reproduces the silica-induced lung injury observed in humans we found that systemic inhibition of NF-kappaB activation with a pharmacologic inhibitor (BAY 11-7085) of IkappaB alpha phosphorylation decreased silica-induced inflammation and collagen deposition. In contrast, transgenic mice expressing a dominant negative IkappaB alpha mutant protein under the control of epithelial cell specific promoters demonstrate enhanced apoptosis and collagen deposition in their lungs in response to silica.

conclusionsAlthough limited by its size, our data support that patients with silicosis appear to have poor outcome following lung transplantation. Experimental data indicate that while the systemic inhibition of NF-kappaB protects from silica-induced lung injury, epithelial cell specific NF-kappaB inhibition appears to aggravate the outcome of experimental silicosis.

Indexed as

AnimalsCytokinesEpithelial CellsFemaleGene Expression RegulationGenes, DominantHumansI-kappa B ProteinsLungLung TransplantationMacrophagesMaleMiceMice, Inbred C57BLMiddle AgedNF-kappa BBAY 11-7085CytokinesI-kappa B ProteinsNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mouseNitrilesRNA, MessengerSilicon DioxideSulfonesTumor Necrosis Factor-alpha

Identifiers

PMID19479048
PMCPMC2682759
OpenAlexW2059277683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.